Sagetis Biotech has received a Nuclis Grant from Catalonia's Government for the Investigation of plasmidic DNA nanoparticles formulation in the Treatment of Cystic Fibrosis (CF)
Barcelona, January 2016 - Sagetis Biotech has received a "NUCLIS" grant from Catalonia's government and has been co-financed with FEDER funds. for the investigation of plasmidic DNA nanoparticles formulation for the treatment of Cystic Fibrosis (CF).
The grant proposal is based on the transfection of gene material to the pulmonary epithelium. Gene therapy is a promising treatment for CF in terms of delivery through pulmonary mucus, high security profile and a big improvement in transfections levels. Sagetis Biotech as a reference company in the gene therapy field is dealing with modulators of adenosine receptors and is also interested in developing candidates that may be nominated for the treatment of CF.
Catalonia Trade & Investment is the public agency that works to attract foreign direct investment to Barcelona and Catalonia, promoting the area as an attractive, innovative and competitive business location.
About FEDER funds
The European Regional Development Fund (ERDF) is one of the main financial instruments of the EUʼs cohesion policy. Its purpose is to contribute to reducing disparities between the levels of development of European regions and to reduce the backwardness of the least favoured regions. Particular attention is paid to regions which suffer from severe and permanent natural or demographic handicaps, such as the northernmost regions with very low population density as well as island, cross-border and mountain regions.
About Sagetis Biotech
Sagetis Biotech is devoted to developing an innovative gene delivery technology to overcome a fundamental engineering challenge in gene therapy: the development of safe and effective delivery vectors. Privately funded and based in Barcelona, Sagetis Biotech was founded in 2010 as a spin-off from GEMAT (Materials Engineering Group) at IQS.